Condition: HCC · Sponsor: Chen Xiaoping
Primary liver cancer is one of the most common malignant tumors in the world, and about 80%\~90% of primary liver cancers are pathologically characterized as hepatocellular carcinoma (HCC). Radical surgery is the main method for patients with HCC to obtain long-term survival. However, the early recurrence rate of high-risk HCC is very high, which seriously affects the overall therapeutic effect.
This description comes directly from the study's public registry record.
WanGuang Zhang · 13886195965 · wgzhang@tjh.tjmu.edu.cn
xiaoping Chen · 027-83663400 · chenxpchenxp@163.com
Always discuss trial participation with your own doctor first.
| Huapeng Sun | Xiangyang, Hubei, China | Recruiting |
| Enyu Liu | Jinan, Shandong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06420440